MCID: MTR012
MIFTS: 58

Mitral Valve Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Mitral Valve Disease

MalaCards integrated aliases for Mitral Valve Disease:

Name: Mitral Valve Disease 12 52 14
Chronic Rheumatic Mitral Valve 12 69
Rheumatic Mitral Valve Regurgitation 12
Rheumatic Mitral Valve Incompetence 12
Rheumatic Disease of Mitral Valve 12
Abnormality of the Mitral Valve 29
Rheumatic Mitral Insufficiency 12
Rheumatic Mitral Valve Changes 12
Rheumatic Mitral Regurgitation 69
Diseases of Mitral Valve 69
Disease of Mitral Valve 12
Mitral Rh Valve Dis. 12

Classifications:



Summaries for Mitral Valve Disease

MalaCards based summary : Mitral Valve Disease, also known as chronic rheumatic mitral valve, is related to mitral valve stenosis and loeys-dietz syndrome 5. An important gene associated with Mitral Valve Disease is NPPA (Natriuretic Peptide A), and among its related pathways/superpathways are TGF-Beta Pathway and Integrin Pathway. The drugs Bupivacaine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Mitral Valve Disease

Diseases in the Mitral Valve Disease family:

Mitral Valve Insufficiency

Diseases related to Mitral Valve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
id Related Disease Score Top Affiliating Genes
1 mitral valve stenosis 11.3
2 loeys-dietz syndrome 5 11.1
3 cardiac valvular dysplasia, x-linked 11.0
4 orthostatic intolerance 10.9
5 tgfbr2-related thoracic aortic aneurysms and aortic dissections 10.9 TGFB2 TGFB3
6 loeys-dietz syndrome 4 10.8 TGFB2 TGFB3
7 pelizaeus-merzbacher-like disease 10.7 ACE AGT
8 suppurative otitis media 10.6 ACE FBN1 NPPA
9 idiopathic corneal edema 10.6 FBN1 TGFB2 TGFB3
10 atrial fibrillation 10.6
11 epidemic typhus 10.6 FBN1 TGFB2 TGFB3
12 atrial septal defect 7, with or without av conduction defects 10.6 ACE NPPA
13 renal clear cell carcinoma 10.6 ACE AGTR1 NPPA
14 cataract, autosomal dominant congenital 4 10.6 ACE AGT AGTR1
15 potato nose 10.6 ACE AGT AGTR1
16 hypodontia of incisors and premolars 10.6 ACE NPPA
17 adenocarcinoma 10.6 ACE AGT AGTR1
18 fibular aplasia ectrodactyly 10.6 ACE AGT AGTR1
19 cascade stomach 10.6 ACE AGT AGTR1
20 renal tubular dysgenesis 10.6 ACE AGT AGTR1
21 bleeding disorder, platelet-type, 21 10.5 FBN1 MMP1 TGFB2
22 congenital bilateral megacalycosis 10.5 ACE AGT AGTR1
23 strawberry gallbladder 10.5 IL10 TGFB2 TGFB3
24 hemoglobin lepore-beta-thalassemia syndrome 10.5 FBN1 MMP1
25 episodic ataxia 10.5 ACE AGT AGTR1
26 epithelial predominant pulmonary blastoma 10.5 ACE NOS3 NPPA
27 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.5 ACE AGTR1 NOS3
28 bernard-soulier syndrome, type a2 10.5 ACE AGTR1 NOS3
29 exocrine pancreatic insufficiency 10.5 ACE AGT AGTR1
30 polymicrogyria, bilateral frontoparietal 10.5 AGTR1 FBN1 NOS3
31 chylocele of tunica vaginalis 10.4 ACE AGT AGTR1 NPPA
32 preeclampsia/eclampsia 1 10.4 AGT AGTR1 NOS3
33 hypertrichosis 10.3 ACE AKT1 NOS3
34 craniosynostosis 7 10.3 ACE AGT FBN1 NPPA
35 laryngostenosis 10.3 ACE AGT AGTR1 MMP1
36 mastoiditis 10.3 FBN1 MMP1 MMP13
37 clitoris cancer 10.3 ACE AGTR1 NOS3 NPPA
38 lymphadenitis 10.3 ACE AGTR1 NOS3 NPPA
39 acrofrontofacionasal dysostosis 10.3 ACE AGT AGTR1 NPPA
40 pyelonephritis 10.3 ACE IL10 NOS3
41 survival motor neuron spinal muscular atrophy 10.3 ACE AKT1 NOS3
42 myositis fibrosa 10.3 IL10 SLC6A4 TPH1
43 trichinosis 10.2 ACE AGT AGTR1 NOS3
44 pulmonary hypertension 10.2
45 joint disorders 10.2 ACE AGT AGTR1 NOS3
46 congestive heart failure 10.2
47 pancreatic acth hormone producing tumor 10.2 FBN1 MMP1 MMP13
48 retinitis pigmentosa 17 10.2 ACE AGER AGT AGTR1
49 cervix uteri carcinoma in situ 10.2 ACE AGT FBN1 NOS3
50 peripheral artery disease 10.2 ACE AGT AGTR1 NOS3

Comorbidity relations with Mitral Valve Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 84)


Accessory Nerve Disease Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alcoholic Cardiomyopathy Anxiety Disorder
Aortic Atherosclerosis Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchiectasis Bronchitis
Cardiac Arrest Cardiogenic Shock
Cardiomyopathy, Familial Hypertrophic Cerebrovascular Disease
Chronic Kidney Failure Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Constrictive Pericarditis
Deficiency Anemia Dermatomycosis
Diabetic Polyneuropathy Disseminated Intravascular Coagulation
Dressler's Syndrome Dyskinesia of Esophagus
Dysthymic Disorder Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Gout Heart Conduction Disease
Heart Disease Hepatitis
Hyperlipidemia, Familial Combined Hyperlipoproteinemia Type Iv
Hypertension, Essential Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis
Hypoglycemia Hypothyroidism
Idiopathic Interstitial Pneumonia Intermediate Coronary Syndrome
Intracranial Embolism Iron Deficiency Anemia
Irritable Bowel Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Mitral Valve Disease:



Diseases related to Mitral Valve Disease

Symptoms & Phenotypes for Mitral Valve Disease

MGI Mouse Phenotypes related to Mitral Valve Disease:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.52 ACE ADAM17 AGER AGT AGTR1 AKT1
2 homeostasis/metabolism MP:0005376 10.5 MMP1 MMP13 NOS3 NPPA PTK2 SLC6A4
3 growth/size/body region MP:0005378 10.48 ACE ADAM17 AGER AGT AGTR1 AKT1
4 immune system MP:0005387 10.39 ACE ADAM17 AGER AGT AGTR1 AKT1
5 hematopoietic system MP:0005397 10.38 ACE ADAM17 AGER AGTR1 AKT1 CXCR4
6 cellular MP:0005384 10.36 AKT1 CXCR4 FBN1 IL10 IL4 MMP13
7 behavior/neurological MP:0005386 10.34 ACE AGER AGT AGTR1 AKT1 FBN1
8 endocrine/exocrine gland MP:0005379 10.3 ACE ADAM17 AKT1 CXCR4 FBN1 IL10
9 mortality/aging MP:0010768 10.28 ACE ADAM17 AGT AGTR1 AKT1 CXCR4
10 muscle MP:0005369 10.22 ADAM17 AGER AGT AKT1 CXCR4 FBN1
11 integument MP:0010771 10.19 ADAM17 AGER AKT1 FBN1 IL10 MMP13
12 digestive/alimentary MP:0005381 10.18 ADAM17 CXCR4 IL10 IL4 NOS3 PTK2
13 nervous system MP:0003631 10.18 AGTR1 AKT1 CXCR4 FBN1 IL10 IL4
14 embryo MP:0005380 10.17 PTK2 TGFB2 TGFB3 ADAM17 AKT1 CXCR4
15 adipose tissue MP:0005375 10.15 ACE AGT AGTR1 AKT1 FBN1 NOS3
16 limbs/digits/tail MP:0005371 10.08 ADAM17 FBN1 IL10 MMP13 NOS3 PTK2
17 liver/biliary system MP:0005370 10 ACE AGT AKT1 IL10 IL4 NOS3
18 normal MP:0002873 9.97 ADAM17 AGER IL10 IL4 NOS3 PTK2
19 renal/urinary system MP:0005367 9.96 ACE AGER AGT AGTR1 CXCR4 FBN1
20 reproductive system MP:0005389 9.9 ACE ADAM17 AGT AKT1 CXCR4 FBN1
21 respiratory system MP:0005388 9.7 FBN1 IL10 IL4 NOS3 PTK2 TGFB2
22 skeleton MP:0005390 9.4 ADAM17 AGER AKT1 CXCR4 FBN1 IL10

Drugs & Therapeutics for Mitral Valve Disease

Drugs for Mitral Valve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
4 Racepinephrine Approved Phase 4
5
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
6
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3 37350-58-6, 51384-51-1 4171
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Remifentanil Approved Phase 4 132875-61-7 60815
9
Cosyntropin Approved Phase 4 16960-16-0 16129617
10
Etomidate Approved Phase 4 33125-97-2 36339 667484
11
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
12
Dobutamine Approved Phase 4 34368-04-2 36811
13
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Candesartan Approved Phase 4 139481-59-7 2541
16
Cabergoline Approved Phase 4 81409-90-7 54746
17
Warfarin Approved Phase 4,Phase 2 81-81-2 6691 54678486
18
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
19
Morphine Approved, Investigational Phase 4 57-27-2 5288826
20
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
21
Butyric Acid Experimental Phase 4 107-92-6 264
22 Simendan Investigational Phase 4 131741-08-7
23
Angiotensin II Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
24 Anesthetics Phase 4,Phase 2,Phase 3,Early Phase 1
25 Anesthetics, Local Phase 4,Phase 2
26 Carticaine Phase 4
27 Central Nervous System Depressants Phase 4,Phase 2,Early Phase 1
28 Epinephryl borate Phase 4
29 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
30 Pharmaceutical Solutions Phase 4
31 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2
32 Sodium Channel Blockers Phase 4,Phase 3,Phase 2
33 Adrenergic Agents Phase 4,Phase 2,Phase 3
34 Adrenergic Antagonists Phase 4,Phase 2,Phase 3
35 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 2,Phase 3
36 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 3
37 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
38 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1
39 Autonomic Agents Phase 4,Phase 2,Phase 3
40 Neurotransmitter Agents Phase 4,Phase 2,Phase 3
41 Sympatholytics Phase 4,Phase 2,Phase 3
42 Anesthetics, General Phase 4,Early Phase 1
43 Anesthetics, Intravenous Phase 4
44 Hypnotics and Sedatives Phase 4
45 Anti-Inflammatory Agents Phase 4,Phase 2
46 Vasodilator Agents Phase 4,Phase 3,Phase 2
47 Analgesics Phase 4,Phase 2
48 Analgesics, Opioid Phase 4
49 Narcotics Phase 4
50 Analgesics, Non-Narcotic Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 236)

id Name Status NCT ID Phase Drugs
1 Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery Unknown status NCT01536717 Phase 4 Articaine hydrochloride 2% solution;Sodium Chloride
2 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
3 Surgical Treatment of Ischemic Mitral Regurgitation Unknown status NCT01368575 Phase 4
4 Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery Unknown status NCT01431222 Phase 4
5 A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation. Completed NCT00166400 Phase 4 metoprolol succinate
6 Propofol Effects on Mitral Valve Annular Velocity Completed NCT01826149 Phase 4 Propofol 1.0mcg;Propofol 2.0mcg;Propofol 3.0mcg
7 Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery Completed NCT00415701 Phase 4 Etomidate;Propofol;Hydrocortisone;NaCl 0.9%
8 Beating Versus Arrested Heart for Mitral Valve Replacement Completed NCT01641614 Phase 4
9 The Effects of Levosimendan During Mitral Valve Surgery Completed NCT01969071 Phase 4 Levosimendan;Dobutamine
10 Angiotensin-II Blockade in Mitral Regurgitation Completed NCT00587470 Phase 4 Candesartan;atacand;Placebo
11 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4 Cabergoline
12 CG Future® Annuloplasty Ring/Band Clinical Trial Completed NCT01074671 Phase 4
13 The Use of Paravertebral Block for Cardiac Surgery Completed NCT02180893 Phase 4
14 General Plus Spinal Anesthesia and General Anesthesia Alone on Right Ventricular Function Recruiting NCT03013075 Phase 4 Bupivacaine heavy and Morphine;General Anesthetics
15 (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Recruiting NCT02592889 Phase 4
16 Early Percutaneous Mitral Intervention in Asymptomatic Moderate Mitral Stenosis Active, not recruiting NCT01406353 Phase 4
17 Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation Active, not recruiting NCT02687932 Phase 4 LCZ696;Valsartan
18 Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses Enrolling by invitation NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
19 Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease Not yet recruiting NCT02982850 Phase 4 Dabigatran;Acetylsalicylic acid;Warfarin
20 High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Trial Comparing MitraClip® to Surgical Therapy Terminated NCT02534155 Phase 4
21 Clinical Evaluation of a Modular Extracorporeal Circulation Circuit Unknown status NCT02000544 Phase 3
22 Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation Unknown status NCT01920698 Phase 3
23 Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease Unknown status NCT01013688 Phase 3
24 Predictors of Postoperative Left Ventricular Function in Patients Undergoing Mitral Valve Repair for Severe Degenerative Mitral Regurgitation Unknown status NCT01519050 Phase 3
25 Safety and Efficacy Study of the Sorin 3D Annuloplasty Ring For Mitral Repair Completed NCT00567853 Phase 3
26 Randomised Ischaemic Mitral Evaluation (RIME) Trial Completed NCT00413998 Phase 3
27 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease) Completed NCT01052428 Phase 2, Phase 3 metoprolol succinate (Toprol XL);Placebo
28 Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm Completed NCT01022463 Phase 3 Ivabradine;Atenolol
29 Cingularbio® Heart Valve Clincial Study Recruiting NCT02755220 Phase 3
30 Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial) Active, not recruiting NCT02435303 Phase 2, Phase 3 Sildenafil;Placebo
31 Safety and Efficacy Study of the PTMA Device to Reduce Mitral Valve Regurgitation in Patients With Heart Failure Suspended NCT00815386 Phase 2, Phase 3
32 Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure Terminated NCT00608140 Phase 3 Optimal medical therapy (OMT)
33 Carbon Dioxide Insufflation on Cerebral Microemboli Terminated NCT00715845 Phase 2, Phase 3
34 Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation Terminated NCT00113698 Phase 3 Enalapril
35 Perioperative Ketorolac-lidocaine in the Patients With Valvular Heart Diseases During Cesarean Delivery Unknown status NCT01571791 Phase 2 Placebo;Ketorolac-Lidocaine
36 Bosentan for Severe Mitral Valve Dysfunction Unknown status NCT01270750 Phase 1, Phase 2 BOSENTAN
37 Safety and Efficacy Study of a New Device for Making Neochordae in Mitral Valve Repair Unknown status NCT01811537 Phase 1, Phase 2
38 Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation Unknown status NCT00833014 Phase 2
39 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation Completed NCT00807040 Phase 2
40 Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery Completed NCT01481350 Phase 2 sildenafil
41 Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery Completed NCT00903370 Phase 2
42 CARDINAL Adjustable Annuloplasty Ring System For Treatment of Mitral Regurgitation Completed NCT01137734 Phase 2
43 Feasibility Study of a Percutaneous Mitral Valve Repair System. Completed NCT00209339 Phase 1, Phase 2
44 Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients Completed NCT00356759 Phase 2 Prolongation of the interval between monitoring of warfarin
45 RESTOR-MV: Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve Completed NCT00120276 Phase 2
46 Aachen Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device to Reduce Mitral Regurgitation Completed NCT00572091 Phase 1, Phase 2
47 RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial Recruiting NCT02303795 Phase 2 Rivaroxaban;Warfarin
48 CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study Recruiting NCT02722551 Phase 1, Phase 2
49 NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation Enrolling by invitation NCT03015194 Phase 2
50 The Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients With Bicuspid Aortic Stenosis Not yet recruiting NCT03163329 Phase 2

Search NIH Clinical Center for Mitral Valve Disease

Genetic Tests for Mitral Valve Disease

Genetic tests related to Mitral Valve Disease:

id Genetic test Affiliating Genes
1 Abnormality of the Mitral Valve 29

Anatomical Context for Mitral Valve Disease

MalaCards organs/tissues related to Mitral Valve Disease:

39
Heart, Testes, Brain, Endothelial, Lung, Whole Blood, Smooth Muscle

Publications for Mitral Valve Disease

Articles related to Mitral Valve Disease:

(show top 50) (show all 635)
id Title Authors Year
1
Concomitant or Staged Transcatheter Treatment for Severe Combined Aortic and Mitral Valve Disease. ( 28579347 )
2017
2
Mitral valve morphology assessed by three-dimensional transthoracic echocardiography in healthy dogs and dogs with myxomatous mitral valve disease. ( 28279678 )
2017
3
Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs. ( 28345991 )
2017
4
Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs. ( 28145607 )
2017
5
Complex robotic correction for complex degenerative mitral valve disease. ( 28203546 )
2017
6
Real-Time 3-Dimensional Echocardiographic Assessment of Effective Regurgitant Orifice Area in Dogs With Myxomatous Mitral Valve Disease. ( 28109120 )
2017
7
A retrospective study of degenerative mitral valve disease in small-breed dogs: Survival and prognostic variables. ( 28057898 )
2017
8
Polymorphisms in the serotonin transporter protein gene in Maltese dogs with degenerative mitral valve disease. ( 28693307 )
2017
9
Assessment of Left Atrial Deformation and Function by 2-Dimensional Speckle Tracking Echocardiography in Healthy Dogs and Dogs With Myxomatous Mitral Valve Disease. ( 28455877 )
2017
10
Cardiomyocyte marker expression in dogs with left atrial enlargement due to dilated cardiomyopathy or myxomatous mitral valve disease. ( 28612341 )
2017
11
Dynamic and quantitative evaluation of degenerative mitral valve disease: a dedicated framework based on cardiac magnetic resonance imaging. ( 28540065 )
2017
12
Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study. ( 28734620 )
2017
13
Prof. Tohru Asai & Prof. Taweesak Chotivatanapong: treatment of mitral valve disease. ( 28890880 )
2017
14
Short-term heart rate variability in dogs with sick sinus syndrome or chronic mitral valve disease as compared to healthy controls. ( 28525326 )
2017
15
Substrate characteristics and ablation outcome of left atrial tachycardia in rheumatic mitral valve disease. ( 28594430 )
2017
16
Deletion of Fstl1 (Follistatin-Like 1) From the Endocardial/Endothelial Lineage Causes Mitral Valve Disease. ( 28705792 )
2017
17
Degenerative mitral valve disease-contemporary surgical approaches and repair techniques. ( 28203540 )
2017
18
Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model. ( 28804599 )
2017
19
Mitral valve repair for degenerative mitral valve disease: surgical approach, patient selection and long-term outcomes. ( 28566474 )
2017
20
Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays. ( 28449360 )
2017
21
Mitral Valve Disease: a Comprehensive Review. ( 28688022 )
2017
22
Pulmonary hypertension and mitral valve disease: Still a beast. ( 28411749 )
2017
23
Exercise Testing and Stress Imaging in Mitral Valve Disease. ( 28290006 )
2017
24
Biologic variability of N-terminal pro-brain natriuretic peptide in healthy dogs and dogs with myxomatous mitral valve disease. ( 28111138 )
2017
25
Serum proteomic profiles in CKCS with Mitral valve disease. ( 28173805 )
2017
26
Quality of Life Score as a Predictor of Death in Dogs with Degenerative Mitral Valve Disease. ( 28380134 )
2017
27
Association of altered collagen content and lysyl oxidase expression in degenerative mitral valve disease. ( 28453968 )
2017
28
Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease. ( 28478943 )
2017
29
Should pre-operative left atrial volume receive more consideration in patients with degenerative mitral valve disease undergoing mitral valve surgery? ( 27855288 )
2017
30
The Cox-Maze IV procedure for atrial fibrillation is equally efficacious in patients with rheumatic and degenerative mitral valve disease. ( 28583297 )
2017
31
Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration. ( 28132441 )
2017
32
Tricuspid annular plane systolic excursion in dogs with myxomatous mitral valve disease with and without pulmonary hypertension. ( 28579307 )
2017
33
Diagnostic accuracy of electrocardiographic P wave related parameters in the assessment of left atrial size in dogs with degenerative mitral valve disease. ( 28845021 )
2017
34
Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease. ( 28576479 )
2017
35
Comparison of cellular changes in Cavalier King Charles spaniel and mixed breed dogs with myxomatous mitral valve disease. ( 26860643 )
2016
36
Preliminary Investigation of Cardiovascular-Renal Disorders in Dogs with Chronic Mitral Valve Disease. ( 27717188 )
2016
37
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( 27678080 )
2016
38
Rheumatic Mitral Valve Disease Is Associated With Worse Outcomes in Stroke: A Thailand National Database Study. ( 27703088 )
2016
39
Differences in atrial fibrillationa89associated proteins between the left and right atrial appendages from patients with rheumatic mitral valve disease: A comparative proteomic analysis. ( 27667121 )
2016
40
Associations of rs3918242 and rs2285053 MMP-9 and MMP-2 polymorphisms with the risk, severity, and short- and long-term complications of degenerative mitral valve diseases: a 4.8-year prospective cohort study. ( 27288746 )
2016
41
Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease. ( 26831162 )
2016
42
Systolic arterial blood pressure estimated by mitral regurgitation velocity, high definition oscillometry, and Doppler ultrasonography in dogs with naturally occurring degenerative mitral valve disease. ( 27037058 )
2016
43
Pulmonary vascular remodeling in mitral valve disease: An optical coherence tomography study. ( 26580335 )
2016
44
Limitations of Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular Calcification: Should it Be Performed Outside the Purview of a Clinical Trial? ( 27931600 )
2016
45
Transcatheter mitral valve implantation for inoperable severely calcified native mitral valve disease: A systematic review. ( 26577250 )
2016
46
Atrial tissue expression of receptor for advanced glycation end-products (RAGE) and atrial fibrosis in patients with mitral valve disease. ( 27372036 )
2016
47
Results of a single-stage hybrid procedure for patients with coronary and mitral valve disease. ( 26922294 )
2016
48
Case images: Left atrial appendage ostial stenosis in a patient with rheumatic mitral valve disease. ( 27665342 )
2016
49
Reply: Limitations of Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular Calcification: Should it Be Performed Outside the Purview of a Clinical Trial? ( 27931601 )
2016
50
Prevalence and Prognosis of Anemia in Dogs with Degenerative Mitral Valve Disease. ( 27840827 )
2016

Variations for Mitral Valve Disease

Expression for Mitral Valve Disease

Search GEO for disease gene expression data for Mitral Valve Disease.

Pathways for Mitral Valve Disease

Pathways related to Mitral Valve Disease according to GeneCards Suite gene sharing:

(show all 43)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.51 AGT AGTR1 AKT1 CXCR4 IL10 IL4
2
Show member pathways
13.34 AKT1 CXCR4 FBN1 MMP1 MMP13 PTK2
3
Show member pathways
13.34 AKT1 CXCR4 IL10 IL4 NOS3 PTK2
4
Show member pathways
13.25 AKT1 CXCR4 IL10 IL4 PTK2 TGFB2
5
Show member pathways
12.83 ACE AKT1 IL10 TGFB2 TGFB3
6
Show member pathways
12.75 AKT1 NOS3 PTK2 TGFB2 TGFB3
7
Show member pathways
12.75 AGT AGTR1 AKT1 CXCR4 NOS3 PTK2
8
Show member pathways
12.64 ACE AGT AGTR1 AKT1 IL4 PTK2
9
Show member pathways
12.63 ADAM17 FBN1 MMP1 MMP13 TGFB2 TGFB3
10
Show member pathways
12.51 AGTR1 AKT1 IL10 NOS3 PTK2
11
Show member pathways
12.44 AKT1 NPPA TGFB2 TGFB3
12
Show member pathways
12.28 AKT1 IL4 MMP1 MMP13
13 12.17 AKT1 IL10 TGFB2 TGFB3
14 12.13 AKT1 MMP1 TGFB2 TGFB3
15 12.1 AGTR1 AKT1 CXCR4 MMP1 PTK2 TGFB2
16
Show member pathways
12.07 AKT1 IL10 IL4 TGFB2 TGFB3
17
Show member pathways
12.01 AKT1 IL10 TGFB2 TGFB3
18 11.89 AKT1 IL10 IL4 MMP1
19
Show member pathways
11.87 IL4 TGFB2 TGFB3
20 11.86 AKT1 TGFB2 TGFB3
21 11.83 AKT1 NOS3 PTK2
22 11.82 AGTR1 AKT1 CXCR4 IL10
23 11.81 MMP1 TGFB2 TGFB3
24 11.79 NOS3 TGFB2 TGFB3
25
Show member pathways
11.77 AKT1 NOS3 PTK2
26 11.76 AKT1 IL4 MMP1
27 11.76 IL10 PTK2 TGFB2 TGFB3
28 11.72 AKT1 CXCR4 PTK2
29
Show member pathways
11.69 FBN1 TGFB2 TGFB3
30 11.63 AKT1 MMP13 TGFB2
31 11.62 ACE AGT AGTR1
32 11.6 AKT1 IL10 IL4
33 11.57 ADAM17 AGER AKT1
34
Show member pathways
11.54 AKT1 PTK2 TGFB2 TGFB3
35 11.49 AGER AKT1 MMP13 NOS3
36 11.47 IL10 TGFB2 TGFB3
37 11.47 IL10 IL4 TGFB2 TGFB3
38
Show member pathways
11.34 IL10 TGFB2 TGFB3
39 11.18 AKT1 TGFB2 TGFB3
40 11.1 AGER AGTR1 AKT1 NOS3 TGFB2 TGFB3
41 11.01 AKT1 NOS3 PTK2
42 10.93 IL4 TGFB2 TGFB3
43 10.61 IL4 TGFB2 TGFB3

GO Terms for Mitral Valve Disease

Cellular components related to Mitral Valve Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 ACE AGT FBN1 IL10 IL4 MMP13
2 extracellular region GO:0005576 9.7 ACE AGER AGT FBN1 IL10 IL4
3 extracellular matrix GO:0031012 9.02 FBN1 MMP1 MMP13 TGFB2 TGFB3

Biological processes related to Mitral Valve Disease according to GeneCards Suite gene sharing:

(show all 45)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.98 ADAM17 IL10 IL4 SLC6A4 TGFB2
2 cellular protein metabolic process GO:0044267 9.96 FBN1 MMP1 MMP13 NPPA
3 aging GO:0007568 9.92 AGT AKT1 IL10 TGFB3
4 positive regulation of protein phosphorylation GO:0001934 9.91 ADAM17 AKT1 IL4 PTK2
5 positive regulation of cell proliferation GO:0008284 9.91 ADAM17 AGT IL4 PTK2 TGFB2
6 transforming growth factor beta receptor signaling pathway GO:0007179 9.87 PTK2 TGFB2 TGFB3
7 response to organic substance GO:0010033 9.87 AKT1 IL10 SLC6A4
8 positive regulation of cell growth GO:0030307 9.85 ADAM17 AKT1 TGFB2
9 extracellular matrix disassembly GO:0022617 9.85 FBN1 MMP1 MMP13
10 cellular response to mechanical stimulus GO:0071260 9.85 AGT AKT1 NPPA
11 regulation of inflammatory response GO:0050727 9.83 AGER AGTR1 IL4
12 B cell differentiation GO:0030183 9.82 ADAM17 IL10 IL4
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 AGT PTK2 TGFB2
14 positive regulation of cell cycle GO:0045787 9.72 IL10 SLC6A4 TGFB2
15 female pregnancy GO:0007565 9.71 AGT IL4 NPPA TGFB3
16 regulation of blood vessel diameter GO:0097746 9.7 ACE AGTR1
17 low-density lipoprotein particle remodeling GO:0034374 9.69 AGT AGTR1
18 nitric oxide biosynthetic process GO:0006809 9.68 AKT1 NOS3
19 angiotensin maturation GO:0002003 9.68 ACE AGT
20 neutrophil mediated immunity GO:0002446 9.67 ACE ADAM17
21 salivary gland morphogenesis GO:0007435 9.67 TGFB2 TGFB3
22 blood vessel remodeling GO:0001974 9.67 ACE AGT NOS3
23 negative regulation of organ growth GO:0046621 9.66 PTK2 SLC6A4
24 response to fluid shear stress GO:0034405 9.65 AKT1 NOS3
25 positive regulation of cholesterol esterification GO:0010873 9.65 AGT AGTR1
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL10 IL4
27 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.63 ADAM17 AKT1
28 epidermal growth factor receptor signaling pathway GO:0007173 9.62 ADAM17 PTK2
29 type 2 immune response GO:0042092 9.61 IL10 IL4
30 regulation of vasoconstriction GO:0019229 9.61 ACE AGT AGTR1
31 positive regulation of NAD(P)H oxidase activity GO:0033864 9.6 AGT AGTR1
32 negative regulation of macrophage cytokine production GO:0010936 9.59 TGFB2 TGFB3
33 renin-angiotensin regulation of aldosterone production GO:0002018 9.58 AGT AGTR1
34 regulation of renal sodium excretion GO:0035813 9.57 AGT AGTR1
35 regulation of isotype switching GO:0045191 9.56 IL10 IL4
36 regulation of blood pressure GO:0008217 9.56 ACE AGT NOS3 NPPA
37 kidney development GO:0001822 9.55 ACE AGT AGTR1 FBN1 TGFB2
38 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.54 AGT AGTR1
39 regulation of blood vessel size GO:0050880 9.54 AGT NOS3 NPPA
40 regulation of complement-dependent cytotoxicity GO:1903659 9.52 IL10 TGFB2
41 positive regulation of cellular protein metabolic process GO:0032270 9.5 AGT AGTR1 AKT1
42 regulation of renal output by angiotensin GO:0002019 9.48 ACE AGT
43 uterine wall breakdown GO:0042704 9.46 TGFB2 TGFB3
44 response to hypoxia GO:0001666 9.17 ADAM17 AGER CXCR4 NPPA SLC6A4 TGFB2
45 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.13 ACE AGT AGTR1

Molecular functions related to Mitral Valve Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 IL10 IL4 TGFB2 TGFB3
2 metallopeptidase activity GO:0008237 9.56 ACE ADAM17 MMP1 MMP13
3 type II transforming growth factor beta receptor binding GO:0005114 9.32 TGFB2 TGFB3
4 type III transforming growth factor beta receptor binding GO:0034714 9.16 TGFB2 TGFB3
5 growth factor activity GO:0008083 9.02 AGT IL10 IL4 TGFB2 TGFB3
6 bradykinin receptor binding GO:0031711 8.96 ACE AGTR1

Sources for Mitral Valve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....